Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,605Revenue (TTM) $M169Net Margin (%)-35.0Altman Z-Score-0.3
Enterprise Value $M2,818EPS (TTM) $-0.3Operating Margin %-99.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-36.1Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio3.0Cash flow > EarningsN
Price/Sales15.35-y EBITDA Growth Rate %--Current Ratio3.1Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-10.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M193ROIC % (ttm)-140.4Gross Margin Increase y-yY

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
ARIAMichael Price 2016-03-31 Add0.23%$4.48 - $6.66
$ 13.52141%Add 31.10%1,075,000
ARIAMichael Price 2015-12-31 Add0.08%$5.78 - $7.19
$ 13.52106%Add 14.45%820,000
ARIAMichael Price 2015-09-30 Add0.15%$5.81 - $9.89
$ 13.5275%Add 30.27%716,500
ARIAJoel Greenblatt 2015-06-30 Sold Out $7.9 - $9.71
$ 13.5253%Sold Out0
ARIAMichael Price 2015-03-31 Buy 0.6%$6.1 - $8.97
$ 13.5283%New holding550,000
ARIAJoel Greenblatt 2015-03-31 Buy $6.1 - $8.97
$ 13.5283%New holding16,344
ARIAGeorge Soros 2014-12-31 Sold Out -0.01%$5.02 - $7.46
$ 13.52115%Sold Out0
ARIAGeorge Soros 2014-09-30 Reduce-0.04%$5.01 - $6.5
$ 13.52132%Reduce -85.00%150,000
ARIAGeorge Soros 2014-06-30 Add0.02%$6.3 - $8.52
$ 13.5296%Add 100.00%1,000,000
ARIAGeorge Soros 2014-03-31 Reduce-0.08%$6.46 - $8.99
$ 13.5274%Reduce -74.36%500,000
ARIAGeorge Soros 2013-12-31 Buy 0.11%$2.2 - $18.8
$ 13.52162%New holding1,950,000
ARIAGeorge Soros 2012-06-30 Sold Out -0.15%$14.6 - $17.82
$ 13.52-17%Sold Out0
ARIAGeorge Soros 2012-03-31 Buy 0.15%$12.73 - $16.32
$ 13.52-2%New holding635,000
ARIAGeorge Soros 2011-12-31 Sold Out -0.07%$8.03 - $12.5
$ 13.5223%Sold Out0
ARIAGeorge Soros 2011-09-30 Buy 0.07%$7.63 - $13.34
$ 13.5228%New holding496,847
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARIA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!

ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-09-22Sell20,000$13.430.67view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-09-15Sell59,369$11.7315.26view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-08-22Sell19,436$10.4729.13view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-08-12Sell25,000$10.528.76view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-07-22Sell18,286$8.1166.71view
Cole Hugh MSVP, Chief Business Officer 2016-06-28Sell6,012$7.0591.77view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-06-22Sell23,999$7.2885.71view
LAVIDAS ATHANESEDirector 2016-06-15Sell76,250$8.2164.68view
Radaelli MassimoDirector 2016-06-14Sell108,569$8.2563.88view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-05-23Sell17,762$8.0867.33view

Quarterly/Annual Reports about ARIA:

News about ARIA:

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Weekly CEO Buys Highlight: Citigroup Inc, ARIAD Pharmaceuticals Inc, Bruker BioSciences Corp, Akamai Aug 08 2009 

More From Other Websites
How trader is showing support for Ariad Sep 23 2016
Ariad Receives Interest as a Buyout Candidate Sep 22 2016
4 health-care stocks to watch Sep 21 2016
Ariad Pharma (ARIA) Stock Surged Today on Takeover Speculation Sep 20 2016
Ariad Shares Rise Amid Speculation of Buyout Target Potential Sep 20 2016
Ariad Shares Rise Amid Speculation of Potential Buyout Sep 20 2016
Ariad Pharmaceuticals (ARIA) Stock Is Monday's 'Chart of the Day' Sep 19 2016
Put seller betting Ariad will hold gains Sep 16 2016
Aerie Pharmaceuticals Skyrockets On Eye Drug News Sep 15 2016
ARIAD Announces Ponatinib Data Presentations at European School of Haematology Annual John Goldman... Sep 15 2016
Ariad Pharmaceuticals Leading Biotechs Higher Sep 14 2016
Last-minute call buyers pile into Ariad Sep 12 2016
ETF’s with exposure to ARIAD Pharmaceuticals, Inc. : September 7, 2016 Sep 07 2016
Incyte’s Profitability Improves, Allowing for Revised Guidance Sep 05 2016
Is Incyte Hurt by Having Only One FDA-Approved Drug? Sep 02 2016
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved Sep 01 2016
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib Aug 31 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 30 2016
ARIAD Completes Rolling Submission of New Drug Application for Brigatinib to the U.S. Food and Drug... Aug 30 2016
ARIAD to Present at the Morgan Stanley Global Healthcare Conference Aug 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)